Stocks and Investing
Stocks and Investing
Wed, September 4, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, September 3, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Paul Matteis Maintained (ACAD) at Hold with Increased Target to $28 on, Sep 3rd, 2019
Paul Matteis of Stifel, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $24 to $28 on, Sep 3rd, 2019.
Paul has made no other calls on ACAD in the last 4 months.
There are 2 other peers that have a rating on ACAD. Out of the 2 peers that are also analyzing ACAD, 0 agree with Paul's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Paul
- Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $40 on, Tuesday, August 27th, 2019
- Danielle Brill of "Raymond James" Reiterated at Strong Buy with Increased Target to $43 on, Friday, May 31st, 2019
Contributing Sources